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Abstract

Lyme disease is the most common vector-borne disease in the United States and has a
high prevalence among people in the northeast. Lyme disease can be a debilitating illness
if not diagnosed early, and can lead to long-term health problems for many patients. This
thesis serves as a review of scientific literature on Lyme disease, with the prevalence,
symptomology, the bacterial mechanism of infection, the diagnostic process,
transmission, and treatment therapies. Further research and development could lead to
better primary care for those suffering with Lyme disease.
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Ticked Off: An analysis of the inadequate diagnosis and treatment of Lyme disease
Lyme disease was first recognized in the 1970s as a debilitating disease, when
several patients in Lyme, Connecticut suffered with swollen joints, paralysis, and severe
chronic fatigue. The underlying cause of these symptoms was unknown and many
patients were misdiagnosed as a result. Scientist Willy Burgdorfer began research on the
infection and discovered the relationship between the common deer tick and the causative
agent of Lyme disease. The bacterium causing the infection was given the name Borrelia
burgdorferi, after the scientist who discovered it (Hyde, 2017; Tilly, Rosa, & Stewart,
2008).
Known as the Great Imitator, Lyme disease can mimic essentially every kind of
disease; it can affect every tissue and organ system of the human body, making it
incredibly difficult to recognize (Holtorf, n.d.; USA, 2011). The current diagnostics for
Lyme disease, as recommended by the Centers for Disease Control and Prevention
(CDC), have poor sensitivity and can show negative results more than 50% of the time in
positively infected individuals (“Lyme Disease Diagnosis,” n.d.). The poor diagnostic
testing leads to a lack of antibiotic treatment and thus a progressive build-up of the
parasitic infection and a greater manifestation of the disease as the organism multiplies.
Once properly diagnosed, this prolonged infection leads to more extensive and possibly
unsuccessful treatment of the disease. On average, patients will see five doctors over the
course of two years before a diagnosis is made, making it more difficult for full recovery.
Thus, 40% of Lyme patients suffer with long-term health problems (ILADS, n.d.).
Because of possible late diagnoses, failed conventional treatment, and immune
suppression, patients often seek alternative health care to find relief from their symptoms

TICKED OFF

5

(Gardner, 2000). This increase of Lyme patients seeking out alternative healthcare merits
further research and study into the safety and efficacy of alternative therapies. Chief of
epidemiology and surveillance for the CDC Lyme disease program, Paul Mead, referred
to Lyme disease as a tremendous public health problem, which augments the need for
further study and research of Lyme disease in effort to increase awareness and obtain
early diagnosis (CDC, 2013).
Incidence
Lyme disease has been reported from forty-nine states, and has been found in
more than fifty countries (Shapiro & Gerber, 2000). It is the most common vector-borne
illness and is the fastest growing infectious disease in the United States. While it is
mostly concentrated in the upper northeast region of the country, it has been reported in
nearly every state and in several countries, and is extending into various regions (CDC,
2016a; Donohoe, Pennington-Gray, & Omodior, 2015). It is estimated there are 30,000
new cases of Lyme disease reported each year in the United States, with the true number
of cases being three to twelve fold higher than the number of reported cases, making
Lyme disease a larger epidemic than Avian Flu, West Nile Virus, and HIV combined
(“CDC provides estimate,” 2013; USA, 2011).
Lyme disease is transmitted to a person through the saliva of a deer tick, Ixodes
scapularis or Ixodes pacificus, and transmission of the bacteria from the tick to the host
requires a minimum of 72 hours. In rare cases a nymph-stage tick can transmit the
bacteria in twenty-four hours (Barbour, n.d.; Fallon, Vaccaro, Romano, Clemente, 2006;
Moore, Nelson, Molins, Mead & Schriefer, 2016). While all people are susceptible to
Lyme disease, it is slightly more prevalent in males than in females, with the majority of
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males infected between the ages five and nine. Cases of Lyme are seen mostly in young
children and the middle-aged, who are between forty-five and fifty-five years of age
(CDC, 2016b).
The risk factors for Lyme disease are mostly environmental. Spending time
outdoors, especially in heavily wooded areas, increases one’s risk for Lyme disease.
While all persons are equally susceptible and there are no genetic predispositions to the
contraction of Lyme disease, there are genetic abnormalities that could worsen the
severity in which Lyme disease is manifested in a particular person. These genetic
abnormalities can specifically enhance the chronic arthritic symptoms (Bramwell,
Teuscher, & Weis, 2014). B. burgdorferi relies on cholesterol to maintain a firm cell
membrane, and research shows that genetic predispositions to elevated cholesterol levels
will cause an individual to have a higher susceptibility to a stronger manifestation and
increased severity of Lyme disease, as represented by the higher numbers of bacteria
found within the body (Toledo, Monzón, Coleman, Garcia-Monco & Benach, 2015).
Symptoms
Lyme disease symptoms continually vary as the disease progresses. Symptoms
originate as local manifestations until it systemically spreads throughout the body. The
first stage begins as the early localized stage, then progresses to the early disseminated,
and evolves into late disseminated stage, which is commonly known as chronic Lyme
disease (Goldstein, Harden, & Schachter, 2004). The early localized stage usually
consists of flu-like symptoms, and most commonly, a red bull’s-eye rash at the site of the
bite, although, only approximately 19% of patients with Lyme disease actually develop a
bulls-eye rash (Smith, Oertle, & Prato, 2014). Perhaps the beginning stage is most
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difficult to diagnose because of the largely inconsistent symptoms, which is a hallmark of
the disease, and the wide variety in which the symptoms can occur (Lyme Research
Alliance, n.d.). As the disease progresses into the early disseminated stage, symptoms
can develop into facial paralysis, tingling and numbness in extremities, severe fatigue,
changes in vision, joint pain, and cardiac abnormalities. The late disseminated stage
exhibits many of the same symptoms, but at a much higher severity. The late stage can
progress into arthritis, neurological conditions such as disorientation, dizziness, shortterm memory loss, inability to concentrate, or most commonly a mental “fog” (Barbour,
n.d.). The late disseminated stage can occur months or years after the initial infection and
usually causes the most severe symptoms. Additional symptoms of this late stage can
include hallucinations, tremors, hypersensitivity to light and sound, seizures, sudden
weakness and blackouts, nerve pain, and temporary amnesia (Goldstein et al., 2004;
“Late stage,” 2017). Lyme disease can mimic a wide variety of other diseases, and
patients are commonly misdiagnosed with a variation of Alzheimer’s disease, arthritis,
systemic Lupus, Amyotrophic Lateral Sclerosis (more commonly known as ALS),
Parkinson’s disease, Multiple Sclerosis, Fibromyalgia, and many others, before an
accurate diagnosis of Lyme disease is made (Lyme Research Alliance, n.d.). In 2001,
patients with Lyme disease were surveyed to determine their overall quality of life and
indicated that living with Lyme can be severely debilitating (Klempner et al., 2001). The
results of the study showed that the average quality of life for a patient with chronic
Lyme disease was worse than that of a patient with Type 2 diabetes, or recovery from a
recent heart attack, and was equivalent to patients with congestive heart failure or
osteoarthritis (ILADS working group, 2004; Johnson & Stricker, 2010). The CDC
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conducted a study which showed that chronic Lyme patients suffer a worse quality of life
when compared to patients with multiple sclerosis and other chronic diseases, combined
with over 40% of patients being unemployed because of Lyme disease and 24% of
patients identified having received some form of disability accommodations (Johnson,
Wilcox, Mankoff, & Stricker, 2014). To further complicate the symptomatic
ramifications of a B. burgdorferi infection is the Jarisch-Herxheimer reaction, in which a
patient will have an intense worsening of symptoms following antibiotic treatment. The
reaction is described as a shock-like state in response to destruction of the bacteria in the
body as a result of antibiotic therapy. While the exact cause is unknown, it is suggested
the worsened symptoms are due to the damaged spirochete releasing its endotoxins into
the body (Maloy, Black, & Segurola, 1998). Overall, the symptoms of a Lyme patient can
be highly variable and can range in intensity, especially if a Jarisch-Herxheimer reaction
occurs and increases the severity of the symptoms for a patient.
Mechanism of infection
The obligate parasite, B. burgdorferi, is a member of Phylum Spirochaetes.
Bacterial parasites of this phylum are characterized by their spiral shape, which allows
for high motility throughout the body (Tilly et al., 2008). Spirochetes, because of their
spiral shape, have the ability to burrow into soft tissue of the human host (Frazer, 2013).
This bacterium chooses to burrow into privileged sites, such as the eye, synovial fluids,
and the brain, which requires a more rigorous treatment approach to eradicate (Sticker &
Middelveen, 2015). Additionally, B. burgdorferi has been identified in every organ of the
body, which is not common amongst most bacterial pathogens. It also has a high affinity
of attraction for the central nervous system (ILADS working group, 2004). The bacterium

TICKED OFF

9

is unique in that it has two flagella at both ends of the spirochete within their outer
membrane, whereas most bacteria have flagella only at one end and extending out of the
outer membrane cell wall (Smith et al., 2014). B. burgdorferi is one of the most
aggressive pathogens to infect the human body and is unique from other spirochetes in
that it has a flat-wave, sinusoidal, and planar appearance, in comparison to others which
may have a helical, more cylindrical appearance. The undulating movement of the
spirochetes as they travel throughout the body allow the bacterium to invade smaller
spaces and denser environments, contributing largely to its pathogenic success (Harman,
Vig, Radolf, & Wolgemuth, 2013).
The life cycle of B. burgdorferi is unique as it progresses through different hosts
and maintains its infectivity within different reservoirs. Because of its survival in dual
environments, the bacterium is incredibly adaptive to its environment. The ability of it to
adapt so efficiently can be attributed to its progression through changes in its outer
surface proteins (Osp), also known as antigenic variation. When the bacteria are active in
a nymph tick, it resides in the midgut and expresses OspA to help maintain survival
within the tick. When the nymph is feeding on a human, the proteins change and the
bacteria down-regulates expression of OspA and upregulates expression of OspC. The
expression of OspC on the bacteria is required for the infection of a healthy mammalian
candidate. The OspC is recognized by the immune system and antibodies are formed as a
result. In response, the bacteria then down-regulate OspC. The outer surface protein VIsE
is then synthesized, which is consistent with the ability of the bacteria to maintain a longterm infection. VIsE remains on the outer surface, and while the exact function is still

TICKED OFF

10

unknown, the VIsE protein serves to continually undergo antigenic variation to evade
immune system attempts of clearing the infection (Tilly, Bestor, & Rosa, 2013).
Perhaps a more concerning method of infection and evasion of the immune cells
is the bacteria’s ability to attack B lymphocytes. Research has shown that when the
bacteria were surrounded by B-cells, the spirochete entered the B-cell and ruptured it. In
addition to rupturing the lymphocytes, the spirochete then can surround itself with the
outer layer of the B cell and conceal itself, thus preventing another immune attack (Grier,
2000).
The blood-brain barrier is a well-known protected environment, which has very
limited permeability. The barrier serves as a safeguard for the brain and central nervous
system from any drastic changes in internal conditions or from toxins that may be present
in the body. Most bacteria, or large molecules are unable to pass through this barrier
(R&D systems, n.d.). However, B. burgdorferi freely passes through it and then resides
deep within the brain tissue. This progression of B. burgdorferi into the brain contributes
mainly to the prominence of neurological symptoms associated with Lyme disease (Grab
et al., 2005). Another study showed the specific ability of the spirochetes to hide in skin
cells, the first organ it infects. Skin fibroblasts and keratinocytes were found to protect B.
burgdorferi from the effects of antibiotics or immune system attempts. So the conclusion
was made, in light of the evidence revealed, eukaryotic cell types serve as an ideal
environment in which Lyme spirochetes can survive long-term (Georgilis, Peacocke, &
Klempner, 1992).

TICKED OFF

11
Diagnosis

The diagnosis of Lyme disease is based on a two-tiered system in which an initial
ELISA test is run to determine the presence of B. burgdorferi antibodies within the
patient. If positive, a western blot is then conducted to confirm results by identifying the
bacterial proteins recognized by those antibodies. However, this approach is somewhat
unreliable, as the two-tiered system misses up to 90% of positive cases (ILADS working
group, 2004). Because the testing for Lyme disease is so unreliable, most clinicians rely
solely on the presentation of symptoms that coincide with the disease. However, this also
presents a problem; while the telltale sign of Lyme disease is erythema migrans, more
commonly called a Bulls Eye rash, only 80% of patients develop a general rash, and of
that 80%, only 19% have the characteristic Bulls-eye rash that is consistent with a
diagnosis. (Dayhoff-Brannigan, 2016; Smith et al., 2014). The ELISA test serves as a
preliminary screening test in which the antibodies in the blood are measured. However,
as discussed above, B. burgdorferi infects the body by specifically evading the immune
system and preventing the body from forming antibodies, this can cause a false negative
as detected by the ELISA test because the specific antibodies to B. burgdorferi will not
be present in the blood. Because of the negative result, many patients do not receive
further testing or treatment (Lyme Research Alliance, n.d.).
Additional diagnostic challenges present when a patient is bitten by Ixodes
scapularis, particularly because this tick species transmits more than one type of
infection. The acute diseases this tick species may contain is highly variable, which can
contribute to a more difficult process of obtaining an accurate diagnosis. The contraction
of a co-infection in addition to the manifestation of Lyme disease may contribute to
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longer lasting and varied symptoms (Krause et al., 2002). The same Ixodes species that
transmits Lyme can also be infected with the agent that causes human granulocytic
anaplasmosis, babesiosis, or ehrlichiosis (Gary, 2006). In some regions, up to 40% of
white-footed mice can be infected with 2 or more tick-borne pathogens. Similarly, in
some regions, up to 66% of patients had antibodies against B. burgdorferi as well as to
Babesia microti (Goldstein, Thompson, Spielman, Krause, 2001). A 2002 study
concluded that concurrent infection by more than one tick-borne pathogen, is common
(Krause et al., 2002).
Changes were recently made in 1995 to the interpretation of the Western blot test,
and the antigen recognition requirements that were necessary for a positive diagnosis of
Lyme disease. Under these changes, the CDC requires at least five out of the ten B.
burgdorferi bands to be recognized by patient IgG antibody. These bands include 18 kDa,
21 kDa, 28 kDa, 30 kDa, 39 kDa, 41 kDa, 45 kDa, 58 kDa, 66 kDa, and 93 kDa. The
changes also require evidence of patient IgM recognizing two out of three B. burgdorferi
proteins to be present, 24 kDa, 39 kDa, and 41 kDa, for a positive diagnosis (CDC,
2001). While the western blot is generally deemed a more reliable test form than the
ELISA test, because it indicates an immune response to a variety of B. burgdorferi
antigens, it is still estimated to only be 80% sensitive because many patients do not
produce antibody to B. burgdorferi antigens (Lyme Research Alliance, n.d.). Thomas
Grier outlined an interesting case for the rejection of the modifications made to the
interpretation of the Western blot test, in which the bands 22, 25, 31, and 34 are all
missing from the list of positive indicators. These bands, however, are all clinically
significant in the history of Lyme disease, as they correlate with the OSP antigens found
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on B. burgdorferi. Additionally, these OSP antigens with the corresponding bands were
targeted by the vaccine that was made and utilized in the 1990s (Angue, 2016; Grier,
2000). Interestingly enough, the bands which are clinically known to correlate with a
positive indication of Lyme disease, are not listed on the bands necessary for a positive
diagnosis. Grier also outlined a study that was conducted to test the changes made to the
interpretation of the western blot test, and showed that under the previous criteria of tests,
66 patients with the history of a tick bite and symptoms consistent with Lyme disease, as
well as a Bull’s eye rash, were all considered to be positive. But with the new changes to
the western blot bands required for a diagnosis, only 20 patients were now considered to
be positive, leaving 46 patients that, according to the new criteria, were not considered to
be positive for Lyme. Further, without a positive diagnosis for Lyme disease, despite the
consistent symptoms, history of a tick bite, or the erythema migrans, the patients could no
longer be treated, as insurance companies do not cover patients without a positive
diagnosis (Grier, 2000).
The poor testing and false negatives consistent with Lyme disease can be
attributed to the narrow range of antigens tested, despite the wide changing variety of
antigens (Petrovic et al., 1998). An additional study was conducted to test the efficacy of
the new updated criteria, and two performance panels were used, the criteria outlined by
the CDC, and the criteria outlined by Boston Biomedica Inc. The sensitivity and
specificity of the western blot were evaluated against each criteria guideline. The results
showed the panel of western blot antigens outlined by Boston Biomedica Inc. were more
sensitive in diagnosing Lyme disease than those used as outlined by the CDC; however,
the specificity of recognizing those without the disease increased with the CDC criteria
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(Tilton, Sand, & Manak, 1997). This research shows the low reliability of the current
diagnostic practices and contributes to the high amount of underreported cases of Lyme
disease.
B. burgdorferi, as outlined in the mechanism of infection section, can hide in the
brain and the cerebrospinal fluid. It does so by altering its outer surface proteins and thus
evading any immune system attempts to create antibodies against it. Because the body
does not recognize the need to make antibodies, no antibodies are made and the patient
will always respond with a seronegative result in any blood test. The lack of reliability of
blood antibody tests is due to the nature of the bacteria itself and its impossibility to
accurately detect. Thus, physicians that are educated about the complexity of Lyme
disease rely largely on the clinical presentations and the wide range of symptoms that
may present (Kaplan, 2004).
The incubation period may also contribute to the lower efficacy of testing. The
amount of time required to show a set of symptoms after initial infection is usually 3-10
days (“Learn More,” n.d.). Thus, patients may see a physician fairly quickly for their
current symptoms. However, the production of IgM antibodies is not detectable until 1-2
weeks after the infection and IgG antibodies usually takes 4-6 weeks to form. Because of
the need for both IgM and IgG antibodies to be present for a positive diagnosis,
antibodies could take up to a month and a half to fully form before a positive diagnosis
can be made (Borchers, Keen, Huntley, & Gershwin, 2015). The presence of antibodies,
then, may not be fully matured at the time the patient is tested.
The discrepancy in accurate diagnoses of Lyme disease contributes to the gross
underreporting of cases. It has been estimated the true number of cases is between 3-and
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12-fold higher than what is reported, which would equate to 90,000- 360,000 actual true
cases (“CDC provides estimate,” 2013). Given the evidence, it can be concluded there is
a very large number of patients that may be living with Lyme disease, but tested negative
and thus could falsely be diagnosed with other diseases based on their symptoms.
Communicability
The CDC designates the transmission of Lyme disease to be transmissible mainly
through the saliva of a tick bite, however, other possible forms of transmission can occur.
Based on the knowledge that only about 2% of tick bites actually result in the formation
of Lyme disease, as outlined by authors Sticker and Middelveen (2015), it would take 15
million tick bites per year to meet the current estimated rate of Lyme disease as expressed
by the CDC (Hu, 2014). This implausible number of tick bites must suggest, then, there is
another method of transmission (Stricker & Middelveen).
B. burgdorferi have been found in blood that is stored for donation, and thus,
patients with Lyme disease are advised and instructed to not donate blood (CDC, 2015).
Additionally, with the knowledge that other spirochetal diseases such as Syphilis and
Relapsing fever cause maternal-fetal transmission, it raises concern for the possible
maternal-fetal transmission of Lyme disease (Alexander & Cox, 1996). While it is
infrequent, there have been several reports of Lyme disease being transmitted from
mother to fetus during pregnancy (Lakos & Solymosi, 2010; Schlesinger, Duray, Burke,
Steere, & Stillman, 1985; Weber, Bratzke, Neubert, Wilske, & Duray, 1988). Based on
studies in animal models of Lyme disease, only acute infection at the beginning of
pregnancy resulted in fetal loss, in contrast to chronic infections which did not increase
abortion rate (Silver et al., 1994). The same study also concluded, though, that direct
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transmission of B. burgdorferi to the fetus was not necessary for death, as the bacterium
was not detected in the fetuses. Perhaps the bacterium targeted the fetus and caused
death, then traveled back to the mother; complete transmission was not found to be
necessary in cases of fetal death. While research on animal models gives much insight to
the pathological effects of B. burgdorferi, results cannot be substituted for a human
model.
In one reported case, a 28-year old female became pregnant, and early in her
pregnancy she contracted Lyme disease. The baby was delivered at 35 weeks with
respiratory difficulty, and the child died within 39 hours. Upon autopsy, the results
showed a wide range of cardiovascular abnormalities. Additionally, spirochetes were
found in the spleen, renal tubules, and bone marrow (Schlesinger et al., 1985). While
complete transmission may not be required for fetal death, as concluded in the first study,
complete transmission is certainly still a cause for fetal death as recorded in the second
study. In another case, a pregnant woman in her first trimester received penicillin
treatment for 7 days after showing the typical Bulls-eye rash. Less than 24 hours after
birth of the child, the child died, and spirochetes were found in samples of the brain and
the liver (Weber et al., 1988). While fetal death is not very common, it is perhaps more
prevalent with infections during early pregnancy rather than third trimester pregnancies
or cases with chronic Lyme.
In addition to maternal-fetal transmission of B. burgdorferi, little research has
been conducted on the transmission of the bacteria through sexual transmission or the
transmission from mother to baby through breast milk (Stricker & Middelveen, 2015).
However, one study shows spirochetes were found in urine and in breast milk from two
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lactating women. This suggests Lyme disease is present in bodily secretions and has the
potential to be transmitted through breast milk, however, the viability of the bacteria was
not recorded (Schmidt et al., 1995). Additionally, a study was conducted to test the
hypothesis that B. burgdorferi could be transmitted through intimate contact. Vaginal and
seminal secretions were obtained from all subjects and 11 out of the 13 secretions
obtained from patients with a positive Lyme disease test had viable, motile spirochetes
present. Further, the tests conducted from 3 couples participating in unprotected sex
showed identical strains of bacteria in their genital secretions, suggesting the direct
transmission through intimate contact (Middelveen et al., 2014). This study, however,
received much criticism from its reviewers, based on the questioning reliability of the
study. There were concerns from the reviewers about the sterility of the samples as well
as the staining process and the need for cross-checking of blind samples to ensure the
bacteria observed was B. burgdorferi. Nevertheless, the study should still be considered,
and while not conclusive, it can strongly suggest the possibility of sexual transmission of
Lyme disease.
One study was conducted to test the possible contact transmission of B.
burgdorferi amongst the Peromyscus leucopus species, also known as the white-footed
mouse, without the need of a tick vector. The study used a group of white-footed mice as
a vector to inoculate with bacteria and house in an environment with uninfected mice.
The results concluded contact transmission was possible, as antibodies were formed in
the uninfected mice, and there were no indications it had been transferred through blood.
This study could offer a probable explanation for the formation of Lyme disease among
some patients with no tick exposure (Burgess, Amundson, Davis, Kaslow, & Edelman,
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1986). In another study, however, with the same species of mice, spirochetes were found
in the urine and feces of mice and the uninfected mice that came in contact with the
infected mice contracted the spirochetes and became infected. The spirochetes were
isolated mainly within the bladder of the mouse species. The study also concluded
possible oral contact transmission through grooming, but also negated the possibility of
maternal-fetal transmission (Wright & Nielsen, 1990). Overall, many of these studies
show strong suggestions and implications, however it can be concluded that the results
from small mammal models cannot definitively be applied to the human body.
Treatment
While the treatment of Lyme disease is highly variable, there are several
treatment methodologies and scientific reasoning for their application. No attempt will be
made to contribute to the ongoing Lyme Wars so prevalent in media today (Hoppel,
2008; Johnson, 2014; Stricker & Lautin, 2003). Lyme disease is said to present a public
health threat of major proportions and the clinical complexity in patients with persistent
symptoms has aroused more attention in the press than many other diseases (Kullberg,
Berende, & van der Meer, 2011). The controversy lies between two organizations,
Infectious Diseases Society of America (IDSA) and International Lyme and Associated
Diseases Society (ILADS). These two organizations differ on the treatment approach, and
the fundamental difference resides in whether or not chronic Lyme disease exists
(Hoppel, 2008). The Institute of Medicine in Washington D.C. regards the Lyme disease
guidelines controversy between IDSA and ILADS as perhaps the most contentious debate
among medical conditions with differing guidelines. The IDSA concluded that the
evidence for persistent, or chronic Lyme disease, is too weak, and thus treatment for it
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cannot be justified. The ILADS, however, acknowledges the low quality of life of those
with long-term symptoms, and deems the clinical presentation as enough evidence to
support long-term treatment, with the goal of treating a persistent infection that may be
present (Johnson, 2014; Johnson & Stricker, 2010). The treatment protocol as advised by
ILADS, is to provide long-term antibiotic therapy for patients that still feel sick after the
routine 30 days of treatment as outlined by the standards of IDSA. IDSA acknowledges
their treatment approach is more generalized based on scientific evidence and it does not
address an individualized approach (Hoppel, 2008). While the debate rages on, the
patients are left with conflicting recommendations, no solid treatment protocol, and
progressively sickened bodies. While the majority of patients with persistent symptoms
seek medical aid, no consensus on adequate treatment, or approach to management of the
disease can be made (Kullberg et al., 2011). This section is to serve as a review to
provide a thought-provoking overview on the treatment efficacy and perhaps evaluate the
gap in medical knowledge in treatment of this disease.
In order to discuss possible treatments, it is advantageous to first discuss the
limitations in the treatment of Lyme disease. Perhaps the most challenging obstacle in
treatment is approaching each patient differently, as not all strains of Borrelia, or
presentations of Lyme disease, respond the same to therapy. This requires a very
specialized and individualized approach for patients, and the most compelling difference
in treatment resides in the duration of therapy. The standard treatment therapy for Lyme
disease is a course of antibiotics, which prevents the manifestation of other diseases that
may arise in a later stage (Borchers et al., 2015). The physiology of B. burgdorferi,
however, allows it to change its outer surface proteins and cell wall shape. The bacterium
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is able to reduce its cell wall and revert to a simpler, spherical form. In reducing its cell
wall, antibiotics that target the cell wall are at a disadvantage when targeting the
bacterium. Similarly, as discussed in the above section, B. burgdorferi tend to occupy
privileged sites, where the immune system cannot access. Thus, if the bacteria remain in
those spaces and lies dormant, antibiotics will be unable to target it, regardless of the
length of treatment (Grier, 2000).
Therapy for early Lyme disease with no complications is fairly simple and has a
high cure rate of 84-95% of cases. The difficulty, then, is presented in the patients with
non-specific symptoms that cannot receive a reliable diagnosis early enough. Treatment
success for patients with a delayed diagnosis is unknown and is underreported, and
adequate treatment for patients with long-term symptoms needs to be further studied and
researched (Kullberg et al., 2011).
Standard treatment guidelines for early Lyme disease in adults, as outlined by
IDSA, consists of a 14-day regimen of doxycycline, amoxicillin, or cefuroxime axetil. In
patients with neurological Lyme, presenting with symptoms consistent with an infection
of the central nervous system, or patients with Lyme carditis that may have been
hospitalized or have symptoms consistent with a heart condition, a 14-day regimen of
intravenous ceftriaxone is recommended. Patients presenting with long-term symptoms,
or an attributed chronic Lyme disease (≥ 6 months) are recommended to not take
antibiotics, yet no other guidelines are given for patients presenting with persistent
symptoms (Wormser et al., 2006). The ILADS, however, do not have a standard
treatment protocol, but rather take into account a variety of factors that would affect the
method of treatment. ILADS evaluates each patient based on age, allergy, prior exposure,
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clinical presentations, ability to tolerate side effects, and possible coinfections to
determine the treatment protocol for that patient. Persistent Lyme is more likely to
respond to intravenous therapy, but oral antibiotic therapy may be administered first to
determine the patient’s response. If antibiotics are the chosen course of treatment, many
of the same antibiotics listed under IDSA’s guidelines are also recommended by ILADS,
which include amoxicillin, azithromycin, cefuroxime, clarithromycin, doxycycline and
tetracycline (ILADS working group, 2004).
The controversy in treatment, then, resides with the duration of treatment. The
duration of treatment is based solely on the persistent symptoms that may present in some
patients. Persistent symptoms following a routine course of 2-4 weeks of antibiotics has
been shown in 25-80% of patients, and a persistent infection that was diagnosed on the
basis of culture or PCR was found in up to 40% of patients (Stricker, 2007). Symptoms
may persist for several reasons, which include a low-grade persistent infection,
sequestration of the bacterium in privileged areas where antibiotics cannot access,
remaining damage from previous active infection, autoimmune response, or an
underlying co-infection that presents with clinical manifestations similar to Lyme disease
(Fallon et al., 2006).
Several studies have shown both the efficacy, and the failure of long-term
antibiotic use in patients with persistent symptoms. In one study of 227 patients with
chronic Lyme disease, all subjects were treated with tetracycline for eleven months and
the outcomes were favorable. At the end of eleven months, 20% of the patients were
cured, 70% of patients had improved conditions, and only 10% of patients had failed
treatment. The symptoms also had improved from month 2 to month 3, which suggests
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extended antibiotic therapy correlates with a better symptomatic outcome in patients
(Donta, 1997). In another study conducted on patients with well-documented Lyme
disease, those who had received previous treatment were administered IV ceftriaxone or
IV placebo for 10 weeks. The result showed an improvement in cognitive function, with a
relapse in cognition after discontinuation (Fallon et al., 2008). Another study conducted
on 66 patients with long-term symptoms received 28 days of IV ceftriaxone, and despite
the slight improvement of fatigue, there was no cognitive improvement among the
patients, although four patients had adverse effects which resulted in hospitalization. This
study concluded that additional antibiotic therapy with ceftriaxone, in treating those with
long-term symptoms of Lyme disease, should not be advised or administered (Krupp et
al., 2003). In another study, patients with a history of Lyme disease that tested negative
for a persistent infection of B. burgdorferi were sampled, and no significant difference
was concluded between the patients that received IV or oral antibiotics compared to those
who received the placebo (Klempner et al., 2001). However, all the subjects used in the
studies that had either no improvement or a negative outcome were seronegative for
Borrelia, which may have contributed to the lack of effectiveness of antibiotics. On the
contrary, perhaps the reason behind why some patients seem to improve on long-term
antibiotics, aside from the placebo effect, is the anti-inflammatory effect of the drugs
(Feder et al., 2007).
There is a discrepancy in results among all of these studies regarding the efficacy
of long-term treatment. However, all patients respond differently, and the possible
benefits must be assessed against the possible risks associated with taking long-term
antibiotics (Dattwyler et al., 1997; Nadelman et al., 1992). Although, one research study
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concluded that long-term antibiotics are worth the risk and are justified in the case of
Lyme disease (Stricker, 2007). Additionally, it is also critical to understand the
differences that occur in every patient with Lyme. The bacterium affects every human
body differently, and thus every patient will respond to therapy differently (Borchers et
al., 2015). Lastly, one study could not conclude any recommendations, and simply stated
there was no answer for patients with long-term symptoms. But rather, the emphasis was
placed on the need for different strategies and proven options to provide relief for Lyme
patients (Melia & Auwaerter, 2016).
One study investigated the experiences of patients with long-term Lyme disease
symptoms and reported the overwhelming majority of patients seek complementary and
alternative medicine to assist in their healing and recovery process. The authors discuss
that in light of Lyme disease being poorly understood and often resistant to conventional
treatment, patients often seek alternative medicine to answer their medically unexplained
condition of long-term symptoms. The complementary and alternative medicine often
included over-the-counter products, mind-body practices, dietary modifications,
acupuncture, and chiropractic care. None of the patients studied had experienced adverse
reactions to the complementary and alternative medicine therapies and patients reported a
greater satisfaction with the practitioners (Ali, Vitulano, Lee, Weiss, & Colson, 2014).
These alternative treatment methods often provide patients more open-mindedness in
treatment and cultivate an individualized approach, rather than the usual standard of care
in a conventional treatment setting. Alternative medicine can be complementary to
conventional medicine and more research should be conducted to further understand the
efficacy and safety of these approaches.
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The use of antibiotics for early treatment of Lyme disease is highly effective, but
after long term symptoms evolve and patients have developed the late disseminated stage,
antibiotic treatment has been shown to have some positive effects, but also possible
negative effects and adverse reactions. The potential benefits and risks of antibiotics are
different for every patient in the late disseminated stage, and there are alternative
treatment methods that should be evaluated in the treatment of Lyme disease. Medical
doctor, surgeon, and Chinese medicine practitioner, Shiroko Sokitch, discusses the
importance of supporting the body throughout a treatment process rather than emphasize
the use antibiotics to forcefully eradicate the infection. While eradicating the Lyme
infection should be of optimal importance, the body and innate immune system should be
well-supported using various methods such as, herbs, acupuncture, nutritional
supplements, or diet, in order for the body to fully heal (personal communication, 2016).
Alternative treatments that specifically target the eradication of disease, combined with
supporting the body, can work together to facilitate the optimal immune function of the
body.
In a mouse model study, Vitamin D was supplemented for mice that had
developed chronic arthritis from a B. burgdorferi infection. The results showed vitamin D
was successful in preventing arthritis from progressing into more severe forms, and also
decreased the symptoms. The results also showed no increased risk of hypercalcemia
from Vitamin D supplementation (Cantorna, Hayes, DeLuca, 1998). An in vitro study of
B. burgdorferi showed grapefruit seed extract worked in inhibiting the bacterium’s
transitional forms, which is known for contributing largely to its pathogenic success.
Grapefruit seed extract has been shown to be highly anti-microbial against bacteria and
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fungi, and have higher therapeutic effects than other well-known anti-bacterial agents.
The substance specifically prevented B. burgdorferi from transitioning into cystic forms
which contribute to its ability to evade the immune system. Prevention of this transitional
form of the bacteria can assist the body in fighting off the infection as it allows the
bacteria to be more easily targeted. While this was an in vitro study, the study suggests
the combination of grapefruit seed extract with antibiotics would be efficient in
eradicating Lyme disease, with supporting evidence to show no severe side effects have
been observed in the medicinal application of grapefruit seed extract (Brorson & Brorson,
2007). Another in vitro study tested the efficacy of whole leaf Stevia extract against B.
burgdorferi spirochetes, biofilms, and persister cells. The effects of Stevia were
compared to common antibiotics such as doxycycline, cefoperazone, and daptomycin,
and their combinations. It was reported the antibiotics were not effective in eliminating
the persister cells of B. burgdorferi, but Stevia was able to eliminate the spirochetes and
the persister cells. The study reported that certain antibiotics promoted the biofilm
formation of the bacterium, which is the cause of the antibiotic resistant nature of the
bacterium. Stevia, however, worked to reduce the biofilm mass and attachment to the
bacteria, thereby contributing to the opportunity to eradicate the infection. The study
concluded the efficacy of Stevia against B. burgdorferi because of its strong antibacterial
properties. The study merits further in vitro research in hopes of implementing this in
clinical practice (Theophilus et al., 2015). Other studies report the safety of high dietary
intake of Stevia, as well as a study on diabetic patients consuming Stevia with no
reported adverse reactions (Hsieh et al., 2003; Thomas & Glade, 2010).
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The maintenance of long-term Lyme disease, particularly those with inconsistent
symptoms, largely has to do with nutritional and lifestyle factors. Many diet
modifications of those with long-term Lyme disease can be made in effort to assist the
healing process. Dr. Rath Research Institute in California tested the efficacy of
naturopathic healthcare treatments, in response to the majority of Lyme patients seeking
alternative options to conventional therapy (Dr. Rath Research Institute, 2015). Many
practical applications were found as a result of the research conducted, with the general
overview consisting of micronutrient supplementation, immune system support,
decreasing inflammation, detoxification, and implementing a proper diet. Applying a
proper diet can perhaps be the most immediate response to the maintenance of Lyme
disease, and the recommendation as outlined by Dr. Rath Research Institute consist of
decreasing inflammation by practicing a gluten and dairy free diet, which works to avoid
further inflammation to a Lyme patient. Digestive functioning of a patient with Lyme
disease is already inhibited, so a low allergen diet is important, especially for those
patients that are on long-term antibiotics, which can cause yeast overgrowth. High
volumes (1L for every 25kg) of clean, filtered water should be consumed to aid in the
constant fluid flow of the body and the natural detoxification process. Lastly, since the
pain experienced by Lyme patients often causes insomnia, adequate sleep is highly
encouraged for healing, and melatonin or other herbs can be supplemented for proper
rest. The overall goal of changing diet and lifestyle of patients with Lyme disease should
be geared towards limiting artificial or processed foods, along with artificial ingredients
that can be found in cleaning and skin-care products. Since Lyme disease downregulates
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the body’s immune system and causes such a wide range of debilitating symptoms, the
importance of limiting any additional toxic load is highlighted by this research.
Treatment options for patients with Lyme disease are highly variable, and the
research shows the need for an individualized approach to each patient. The efficacy of
treatment in early stages are very positive, but if the diagnosis of the disease is delayed
and Lyme disease sets into the late disseminated stage, treatment can require a much
more aggressive approach and has a lower rate of efficacy. In the late disseminated stage,
the focus should shift from treatment to the maintenance of its symptoms. Long-term
Lyme disease should be managed until treatment options for these patients are fully
researched and available.
Conclusion
Lyme disease presents several different challenges, for both the patient and the
health care provider. Despite its growing incidence in the United States, Lyme disease is
commonly misdiagnosed, which demands for increased awareness among the medical
community, in effort to stress the importance of early diagnosis. The shrewd mechanism
of infection used by B. burgdorferi classifies it as an excellent pathogen, but merits
further study to increase the effectiveness of treatment methods. Additionally, more
research into the transmission of Lyme disease is warranted. Perhaps the most important
area of research should be on further treatment options for those experiencing long-term
symptoms. Conventional and alternative healthcare practices can combine efforts to
optimize the patient’s well-being and facilitate healing. Overall, Lyme disease can be a
debilitating disease with severe consequences if not treated early, and further research
should be conducted in effort to provide early relief for those suffering.
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